Sugi Predict

Sugi Predict / Compounds / SCHEMBL15768798

SCHEMBL15768798

SCHEMBL15768798

Nc1ccn([C@]2(C=O)O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.49
▸ PDE3A Q14432 3/20 0.49
▸ MTOR P42345 2/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ SLC29A1 Q99808 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ MDM2 Q00987 1/20 0.49
▸ NCOA1 Q15788 1/20 0.49
▸ NCOA3 Q9Y6Q9 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 3/20 0.37
▸ CACNA1F O60840 2/20 0.37
▸ ALB P02768 2/20 0.37
▸ CACNA1D Q01668 2/20 0.37
▸ CACNA1S Q13698 2/20 0.37
▸ CACNA1C Q13936 2/20 0.37
▸ GMNN O75496 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111578 0.89 PDE3A (0.48) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL7201752 0.83 LMNA (0.51) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL30514296 0.83 LMNA (0.53) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL3432521 0.81 LMNA (0.52) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL5491556 0.81 LMNA (0.52) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL23496606 0.81 LMNA (0.52) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL22631542 0.81 LMNA (0.52) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL366599 0.81 LMNA (0.52) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL7539951 0.81 LMNA (0.51) LMNAPDE3AMTORPDE4DSLC29A1
SCHEMBL158512 0.81 LMNA (0.51) LMNAPDE3AMTORPDE4DSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3157573-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 — — EP claimed
WO-2015196128-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 — — WO claimed
US-20260146264-A1 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS FACTOR BIOSCIENCE INC. (US) 2026-05-28 — — US disclosed
US-20260108554-A1 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS FACTOR BIOSCIENCE INC (US) 2026-04-23 — — US disclosed
CN-119866376-A Self-amplifying RNA encoding influenza virus antigen 辉瑞公司 2025-04-22 — — CN disclosed
WO-2024229116-A2 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS FACTOR BIOSCIENCE INC. (US) 2024-11-07 — — WO disclosed
EP-4298214-A1 NUCLEIC ACID VECTORS AND METHODS OF USE Intergalactic Therapeutics, Inc. (US) 2024-01-03 — — EP disclosed
WO-2023215724-A1 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS FACTOR BIOSCIENCE INC. (US) 2023-11-09 — — WO disclosed
WO-2023141602-A2 ENGINEERED RETRONS AND METHODS OF USE RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-07-27 — — WO disclosed
WO-2023081526-A1 LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES ORNA THERAPEUTICS, INC. (US) 2023-05-11 — — WO disclosed
EP-4106800-A1 BASIC DOMAIN-DELETED DNASE1-LIKE 3 AND USES THEREOF Neutrolis, Inc. (US) 2022-12-28 — — EP disclosed
WO-2022182795-A1 NUCLEIC ACID VECTORS AND METHODS OF USE Intergalactic Therapeutics, Inc. (US) 2022-09-01 — — WO disclosed
EP-3510157-A1 PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE Bluebird Bio, Inc. (US) 2019-07-17 — — EP disclosed
WO-2018049226-A9 PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE BLUEBIRD BIO, INC. (US) 2018-09-20 — — WO disclosed
US-20180170990-A1 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS MODERNATX, INC. 2018-06-21 — — US disclosed
WO-2018049226-A1 PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE BLUEBIRD BIO, INC. (US) 2018-03-15 — — WO disclosed
US-9050297-B2 Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator MODERNA THERAPEUTICS, INC. (US) 2015-06-09 — — US disclosed
US-20140161873-A1 MODIFIED POLYNUCLEOTIDES ENCODING ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR MODERNA THERAPEUTICS, INC. (US) 2014-06-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108554-A1 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS B2M, MYADM, CD74 LMNA 407/4885PDE3A 4799/4885MTOR 4088/4885
US-20180170990-A1 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS POLN, POLRMT, MSH2 LMNA 160/4885PDE3A 3546/4885MTOR 4805/4885
US-20260146264-A1 METHODS FOR REPROGRAMMING AND GENE EDITING CELLS ZMYND8, STING1, DCLRE1A LMNA 2027/4885PDE3A 4793/4885MTOR 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.